We are monitoring the impact of COVID-19 on Cancer Immunotherapy Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1336
Share on
Share on

Global Cancer Immunotherapy Market Size, Share, Trends, Growth, COVID-19 Analysis Report – Segmented By Type of Therapies, Area of Therapy (Blood Cancer, Prostate Cancer, Melanoma, Breast Cancer, Lung Cancer, Colorectal Cancer & Other Minor Areas) and Region - Industry Forecast (2021 to 2026)

Pulished: April, 2021
ID: 1336
Pages: 182

Cancer Immunotherapy Market Size (2021 to 2026)

As per our report, the global cancer immunotherapy market size is forecasted to grow at a CAGR of 12.52% from 2021 to 2026. This market is forecasted to worth USD 178.5 billion by 2026 from USD 99.02 billion in 2021.

Immunotherapy, which is also known as biologic therapy, can be performed in two ways. That is by stimulating one’s immune system to fight against the disease by attacking defective cancer cells and giving constituents of the immune system from outside such as synthetic proteins into the body to fight against the disease. It is performed to treat cancer patients for a long time, even when doctors do not thoroughly understand the immune system. Immunotherapy is a treatment option that uses certain parts of an immune system to fight against various diseases such as cancer.

Cancer immunotherapy is a type of therapy used to treat various cancer diseases that involves stimulation and suppression of the immune system. It is made of white blood cells, organs, and tissue of the lymphatic system. Several companies are investing massive amounts in the treatment of cancer. Currently, U.S. food and administration has approved 32 various immunotherapies to treat 20 cancer types, including cell-based immunotherapies, immunomodulators, BCG vaccines, targeted therapies, and oncotic viruses.

MARKET DRIVERS:

The growing occurrence of cancer, the rising number of R & D, and technological developments in treatment options are majorly fuelling the global cancer immunotherapy market.

Cancer has now become one of the leading causes of death throughout the world. According to the statistics published by the World Health Organization (WHO), an estimated 9.6 million were died of cancer in the year 2018 and also found tobacco as the leading risk factor for cancer and recorded 22% of responsibility in cancer deaths happened in 2018. The noticed increasing prevalence of cancer is estimated to favor the growth of the global cancer immunotherapy market.

Additionally, the global cancer immunotherapy is fuelled by the high efficacy of immunotherapy compared to other treatments, fewer side effects associated with cancer immunotherapy, reduced the chance of recurrence of cancer. Some of the other notable drivers expanding the market size are technological advances in clinical therapies, an increase in the number of R&Ds for cancer treatment, and the specificity and efficacy of cancer immunotherapy to treat a wide range of cancers.

The rising adoption of advanced therapeutics for cancer and growing implementation in the healthcare sector to treat cancer diseases is also supporting the growth of the global cancer immunotherapy market. Also, public organizations are focusing on investment in Research and development activities to develop new cancer immunotherapy. The development of CAR –T cell therapy is also propelling the market growth.

MARKET RESTRAINTS:

The primary factor restraining the growth of the market is various cancer like Melanoma shows resistance to chemotherapy and radiation therapies, Cost of cancer therapies, limited information on cancer immunobiology. Furthermore, the high competition in the product development cycle is restraining the demand of the market. Depending upon the cancer types and cancer patients, it is complicated to develop a new drug with high quality, which impedes the market's demand. Also, lack of skill professional and lack of awareness among the people hamper the market growth.

Impact of COVID-19 on the cancer immunotherapy market:

COVID-19 has a positive impact on the healthcare sector. World health organization announced the COVID-19 as a pandemic on March 11, 2020. During the first half of 2020, the cancer immunotherapy market was slightly reduced due to the lockdown restrictions and ban on travel. There was an increase in the cancer patient rate, but the world was focused on fighting against coronavirus, many cancer treatments have been postponed. As there is a high risk for cancer patients due to COVID 19, they need to stay home. The treatment procedures for the cancer patients were resumed from the last months with the preventive measures as it is mandatory to give continuous treatment for the cancer patients. The market shares are expected to grab the highest growth rate by 2021. 

Multiple therapeutic regimens are being followed across various countries to come up with reliable cancer treatment. Immunotherapy is a type of cancer treatment that boosts the human immune system to fight against cancer cells. But cancer treatment therapies have been stopped and postponed by various hospitals worldwide due to the sudden outburst of the COVID-19 pandemic. Many countries have been impacted negatively by coronavirus. No activities related to cancer therapies have been done due to the unavailability of doctors and medical centers, but the cancer patients need to have surveillance on the conditions regularly. This is expected to result in industry growth over the forecast period.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2020 to 2026

Base Year

2020

Forecast Period

2021 to 2026

Segments Covered

By Type of Therapies, Area of therapy, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East, and Africa

 

This market research report on the global cancer immunotherapy market has been segmented and sub-segmented based on the type of therapies, area of therapy, and region.

Cancer Immunotherapy Market – By Type of Therapies:

  • Immune System Modulators
  • Immune Checkpoint Inhibitors
  • Monoclonal Antibodies

Based on the type of therapies, the monoclonal antibodies segment is expected to dominate the global cancer immunotherapy market during the forecast period and had accounted leading share in 2020. The rise in monoclonal antibodies to treat a wide variety of cancers like breast cancer, lymphoma, lung cancer, brain cancer, cervical cancer, and others is the primary trend driving the market. Because of the high drug specificity towards cancer cells, this is mainly attributed to the technological superiority of this approach. These drugs are designed to identify and create a targeted immune response to cancer cells based on their proteins on the cell surface and forgo normal cells.

The monoclonal antibody segment has the most significant growth in the previous year due to high R & D investment in R&D. Some monoclonal antibodies are used for the targeted treatment of cancer. There are various types of monoclonal antibodies, such as naked, conjugated, and bispecific monoclonal antibodies. Now AbbVie product Adalimumab monoclonal antibody was the highest selling product in 2019.

Cancer Immunotherapy Market – By Area of Therapy:

Based on therapy, there is increasing use of cancer immunotherapy for melanoma therapy. Melanoma segment growth can be directly linked to new product development, many FDA approvals, and extensive research and development in this area. The U.S. FDA has recently approved three melanoma treatment checkpoint inhibitors, three cytokine therapies, and one oncolytic virus therapy.

Lung cancers had the most substantial market revenue in 2019. In 2020, the U.S. food and drug administration approved Tabrecta (Capmatinib) to treat non-small cell lung cancer. Melanoma is the fastest-growing segment due to advanced new development in the cancer immunotherapy market.

Cancer Immunotherapy Market – By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

Last Year, North America held the largest share of the revenue in the global cancer immunotherapy market. Increasing disease incidence, increasing accessibility to modern therapy, combined with a growing geriatric population, lead to regional market development. The North American market is further growing due to the highest cancer caused population, aged population, and modern lifestyle in the region. There is a noticeable increase in the biotechnology companies in the U.S. compared to the previous year, driving the cancer immunotherapy market in North America.

Europe has significant growth in the cancer immunotherapy market due to advanced technology and various clinical trials performed in Europe.

Throughout the forecast period, Asia Pacific is expected to experience the fastest growth. Chinese and Japan are introducing new and sophisticated immunotherapy medications. These countries have many current clinical trials for new drug molecules and alternative treatments, and FDA approvals. Approval of new treatment drugs in China and Japan is improving the tumor treatment acceptance of immunotherapy.

Recently, food and drug administration approved new technologies and implementation in China and Japan to treat small-cell lung cancer. India is driving the cancer immunotherapy market due to the vast population and genetic variation. The recent FDA approval and new drug introduction in the market are propelling the market growth.

KEY MARKET PLAYERS:

Companies leading the global cancer immunotherapy market profiled in the report are F. Hoffmann-La Roche Ltd, Amgen, Viralytics, Novartis Pharmaceuticals Corporation, Pfizer, GlaxoSmithKline Pharmaceuticals Limited, AstraZeneca plc, Medivation, Advaxis, Bristol-Myers Squibb, Merck & Co, Celgene Corp, and Immunomedics.

SOME OF THE MOST RECENT HAPPENINGS IN THIS MARKET IN THE RECENT PAST:

  • In 2019, Roche Holding AG received approval to launch its atezolizumab new cancer immunotherapy in India. It is beneficial to treat small cell lung cancer patients with chemotherapy. Also, the company wants to expand its developed market in India for the treatment of cancer disorders. 
  • In 2019, Merck introduced new cancer immunotherapy, Keytruda, with Pfizer Inlyta to minimize kidney cancer disease risk. The drug will give a high response rate and improved progression as compared to treatment with chemotherapy. 
  • In March 2020, Forty-seven was acquired by Gilead Life sciences. This acquisition has helped Gilead to expand its global cancer immunotherapy treatment for various diseases. Forty-seven has lead product magrolimab, and it is a monoclonal antibody used for the treatment of acute myeloid leukemia and B-cell lymphoma.
  • In October 2015, the FDA approved the first oncolytic virus therapy known as Talimogene laherparepvec (T-VEC or Imlygic). The vaccine is used to treat metastatic melanoma that cannot be eliminated by surgery.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market              

5. Market Segmentation

                5.1 Application                 

                                5.1.1 Introduction           

                                5.1.2 Breast       

                                5.1.3 Lung          

                                5.1.4 Melanoma              

                                5.1.5 Colorectal

                                5.1.6 Head & Neck          

                                5.1.7 Prostate   

                                5.1.8 Others      

                                5.1.9  Y-o-Y Growth Analysis, By Application        

                                5.1.10  Market Attractiveness Analysis, By Application    

                                5.1.11  Market Share Analysis, By Application     

                5.2 Product Type                             

                                5.2.1 Introduction           

                                5.2.2 Monoclonal Antibodies     

                                5.2.3 Checkpoint inhibitors/immune modulators              

                                5.2.4 Therapeutic cancer vaccines            

                                5.2.5 Oncolytic virus immunotherapy     

                                5.2.6 Cytokines

                                5.2.7 Adoptive T cell transfer     

                                5.2.8 Adjuvant Immunotherapy

                                5.2.9 Interferons             

                                5.2.10 Interleukins         

                                5.2.11 BCG         

                                5.2.12 Others   

                                5.2.13  Y-o-Y Growth Analysis, By Product Type  

                                5.2.14  Market Attractiveness Analysis, By Product Type

                                5.2.15  Market Share Analysis, By  Product Type

                5.3 Mode of Administration                        

                                5.3.1 Introduction           

                                5.3.2 Intravenous           

                                5.3.3 Oral            

                                5.3.4 Topical      

                                5.3.5 Intra Vesical           

                                5.3.6  Y-o-Y Growth Analysis, By Mode of Administration

                                5.3.7  Market Attractiveness Analysis, By Mode of Administration             

                                5.3.8  Market Share Analysis, By Mode of Administration              

                5.3 End users                    

                                5.3.1 Introduction           

                                5.3.2 Hospitals  

                                5.3.3 Clinics        

                                5.3.4  Y-o-Y Growth Analysis, By End users           

                                5.3.5  Market Attractiveness Analysis, By End users          

                                5.3.6  Market Share Analysis, By End users           

6. Geographical Analysis

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Application

                                                6.1.3.3 By Product Type

                                                6.1.3.4 By Mode of Administration

                                                6.1.3.5 By End users

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Application

                                                6.1.4.3 By Product Type

                                                6.1.4.4 By Mode of Administration

                                                6.1.4.5 By End users

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Application

                                                6.1.5.3 By Product Type

                                                6.1.5.4 By Mode of Administration

                                                6.1.5.6 By End users

                6.2 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

                6.3 Europe                         

                                6.2.1 Introduction           

                                6.2.2 U.K             

                                6.2.3 Spain         

                                6.2.4 Germany 

                                6.2.5 Italy           

                                6.2.6 France      

                6.4 Asia-Pacific                 

                                6.3.1 Introduction           

                                6.3.2 China         

                                6.3.3 India          

                                6.3.4 Japan        

                                6.3.5 Australia  

                                6.3.6 South Korea           

                6.5 Latin America                            

                                6.4.1 Introduction           

                                6.4.2 Brazil         

                                6.4.3 Argentina

                                6.4.4 Mexico     

                                6.4.5 Rest of Latin America         

                6.6 Middle East & Africa               

                                6.5.1 Introduction           

                                6.5.2 Middle-East            

                                6.5.3 Africa        

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 F. Hoffmann-La Roche Ltd                    

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Amgen                         

                8.3 Viralytics                      

                8.4 Novartis Pharmaceuticals Corporation                            

                8.5 Pfizer                            

                8.6 GlaxoSmithKline Pharmaceuticals Limited                     

                8.7 AstraZeneca plc                        

                8.8 Medivation                

                8.9 Advaxis                        

                8.10 Bristol-Myers Squibb                           

                8.11 Merck & Co. and Celgene Corp                        

                8.12 Immunomedics                      

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                          

        a) List of Tables

        b) List of Figures

 

  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Cancer Immunotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  2. Global Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Billion)
  3. Global Breast Market, By Region, From 2021 to 2026 (USD Billion)
  4. Global Lung Market, By Region, From 2021 to 2026 (USD Billion)
  5. Global Melanoma Market, By Region, From 2021 to 2026 (USD Billion)
  6. Global Colorectal Market, By Region, From 2021 to 2026 (USD Billion)
  7. Global Head & Neck Market, By Region, From 2021 to 2026 (USD Billion)
  8. Global Prostate Market, By Region, From 2021 to 2026 (USD Billion)
  9. Global Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Billion)
  10. Global Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Billion)
  11. Global Checkpoint inhibitors/immune modulators Market, By Region, From 2021 to 2026 (USD Billion)
  12. Global Therapeutic cancer vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  13. Global Oncolytic virus immunotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  14. Global Cytokines Market, By Region, From 2021 to 2026 (USD Billion)
  15. Global Adoptive T cell Transfer Market, By Region, From 2021 to 2026 (USD Billion)
  16. Global Adjuvant immunotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  17. Global Interferons Market, By Region, From 2021 to 2026 (USD Billion)
  18. Global Interleukins Market, By Region, From 2021 to 2026 (USD Billion)
  19. Global BCG Market, By Region, From 2021 to 2026 (USD Billion)
  20. Global Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Billion)
  21. Global Intravenous Market, By Region, From 2021 to 2026 (USD Billion)
  22. Global Oral Market, By Region, From 2021 to 2026 (USD Billion)
  23. Global Topical Market, By Region, From 2021 to 2026 (USD Billion)
  24. Global Intravesical Market, By Region, From 2021 to 2026 (USD Billion)
  25. Global Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Billion)
  26. Global hospitals Market, By Region, From 2021 to 2026 (USD Billion)
  27. Global Clinics Market, By Region, From 2021 to 2026 (USD Billion)
  28. North America Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Billion)
  29. North America Breast Market, By Region, From 2021 to 2026 (USD Billion)
  30. North America Lung Market, By Region, From 2021 to 2026 (USD Billion)
  31. North America Melanoma Market, By Region, From 2021 to 2026 (USD Billion)
  32. North America Colorectal Market, By Region, From 2021 to 2026 (USD Billion)
  33. North America Head & Neck Market, By Region, From 2021 to 2026 (USD Billion)
  34. North America Prostate Market, By Region, From 2021 to 2026 (USD Billion)
  35. North America Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Billion)
  36. North America Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Billion)
  37. North America Checkpoint inhibitors/immune modulators Market, By Region, From 2021 to 2026 (USD Billion)
  38. North America Therapeutic cancer vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  39. North America Oncolytic virus immunotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  40. North America Cytokines Market, By Region, From 2021 to 2026 (USD Billion)
  41. North America Adoptive T cell Transfer Market, By Region, From 2021 to 2026 (USD Billion)
  42. North America Adjuvant immunotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  43. North America Interferons Market, By Region, From 2021 to 2026 (USD Billion)
  44. North America Interleukins Market, By Region, From 2021 to 2026 (USD Billion)
  45. North America BCG Market, By Region, From 2021 to 2026 (USD Billion)
  46. North America Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Billion)
  47. North America Intravenous Market, By Region, From 2021 to 2026 (USD Billion)
  48. North America Oral Market, By Region, From 2021 to 2026 (USD Billion)
  49. North America Topical Market, By Region, From 2021 to 2026 (USD Billion)
  50. North America Intravesical Market, By Region, From 2021 to 2026 (USD Billion)
  51. North America Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Billion)
  52. North America hospitals Market, By Region, From 2021 to 2026 (USD Billion)
  53. North America Clinics Market, By Region, From 2021 to 2026 (USD Billion)
  54. United States Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Billion)
  55. United States Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Billion)
  56. United States Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Billion)
  57. United States Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Billion)
  58. Canada Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Billion)
  59. Canada Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Billion)
  60. Canada Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Billion)
  61. Canada Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Billion)
  62. Europe Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Billion)
  63. Europe Breast Market, By Region, From 2021 to 2026 (USD Billion)
  64. Europe Lung Market, By Region, From 2021 to 2026 (USD Billion)
  65. Europe Melanoma Market, By Region, From 2021 to 2026 (USD Billion)
  66. Europe Colorectal Market, By Region, From 2021 to 2026 (USD Billion)
  67. Europe Head & Neck Market, By Region, From 2021 to 2026 (USD Billion)
  68. Europe Prostate Market, By Region, From 2021 to 2026 (USD Billion)
  69. Europe Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Billion)
  70. Europe Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Billion)
  71. Europe Checkpoint inhibitors/immune modulators Market, By Region, From 2021 to 2026 (USD Billion)
  72. Europe Therapeutic cancer vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  73. Europe Oncolytic virus immunotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  74. Europe Cytokines Market, By Region, From 2021 to 2026 (USD Billion)
  75. Europe Adoptive T cell Transfer Market, By Region, From 2021 to 2026 (USD Billion)
  76. Europe Adjuvant immunotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  77. Europe Interferons Market, By Region, From 2021 to 2026 (USD Billion)
  78. Europe Interleukins Market, By Region, From 2021 to 2026 (USD Billion)
  79. Europe BCG Market, By Region, From 2021 to 2026 (USD Billion)
  80. Europe Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Billion)
  81. Europe Intravenous Market, By Region, From 2021 to 2026 (USD Billion)
  82. Europe Oral Market, By Region, From 2021 to 2026 (USD Billion)
  83. Europe Topical Market, By Region, From 2021 to 2026 (USD Billion)
  84. Europe Intravesical Market, By Region, From 2021 to 2026 (USD Billion)
  85. Europe Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Billion)
  86. Europe hospitals Market, By Region, From 2021 to 2026 (USD Billion)
  87. Europe Clinics Market, By Region, From 2021 to 2026 (USD Billion)
  88. U.K. Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Billion)
  89. U.K. Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Billion)
  90. U.K. Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Billion)
  91. U.K. Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Billion)
  92. Germany Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Billion)
  93. Germany Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Billion)
  94. Germany Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Billion)
  95. Germany Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Billion)
  96. France Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Billion)
  97. France Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Billion)
  98. France Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Billion)
  99. France Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Billion)
  100. Italy Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Billion)
  101. Italy Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Billion)
  102. Italy Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Billion)
  103. Italy Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Billion)
  104. Spain Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Billion)
  105. Spain Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Billion)
  106. Spain Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Billion)
  107. Spain Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Billion)
  108. Asia-Pacific Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Billion)
  109. Asia-Pacific Breast Market, By Region, From 2021 to 2026 (USD Billion)
  110. Asia-Pacific Lung Market, By Region, From 2021 to 2026 (USD Billion)
  111. Asia-Pacific Melanoma Market, By Region, From 2021 to 2026 (USD Billion)
  112. Asia-Pacific Colorectal Market, By Region, From 2021 to 2026 (USD Billion)
  113. Asia-Pacific Head & Neck Market, By Region, From 2021 to 2026 (USD Billion)
  114. Asia-Pacific Prostate Market, By Region, From 2021 to 2026 (USD Billion)
  115. Asia-Pacific Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Billion)
  116. Asia-Pacific Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Billion)
  117. Asia-Pacific Checkpoint inhibitors/immune modulators Market, By Region, From 2021 to 2026 (USD Billion)
  118. Asia-Pacific Therapeutic cancer vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  119. Asia-Pacific Oncolytic virus immunotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  120. Asia-Pacific Cytokines Market, By Region, From 2021 to 2026 (USD Billion)
  121. Asia-Pacific Adoptive T cell Transfer Market, By Region, From 2021 to 2026 (USD Billion)
  122. Asia-Pacific Adjuvant immunotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  123. Asia-Pacific Interferons Market, By Region, From 2021 to 2026 (USD Billion)
  124. Asia-Pacific Interleukins Market, By Region, From 2021 to 2026 (USD Billion)
  125. Asia-Pacific BCG Market, By Region, From 2021 to 2026 (USD Billion)
  126. Asia-Pacific Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Billion)
  127. Asia-Pacific Intravenous Market, By Region, From 2021 to 2026 (USD Billion)
  128. Asia-Pacific Oral Market, By Region, From 2021 to 2026 (USD Billion)
  129. Asia-Pacific Topical Market, By Region, From 2021 to 2026 (USD Billion)
  130. Asia-Pacific Intravesical Market, By Region, From 2021 to 2026 (USD Billion)
  131. Asia-Pacific Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Billion)
  132. Asia-Pacific hospitals Market, By Region, From 2021 to 2026 (USD Billion)
  133. Asia-Pacific Clinics Market, By Region, From 2021 to 2026 (USD Billion)
  134. Japan Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Billion)
  135. Japan Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Billion)
  136. Japan Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Billion)
  137. Japan Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Billion)
  138. China Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Billion)
  139. China Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Billion)
  140. China Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Billion)
  141. China Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Billion)
  142. India Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Billion)
  143. India Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Billion)
  144. India Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Billion)
  145. India Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Billion)
  146. South korea Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Billion)
  147. South korea Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Billion)
  148. South korea Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Billion)
  149. South korea Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Billion)
  150. Australia Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Billion)
  151. Australia Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Billion)
  152. Australia Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Billion)
  153. Australia Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Billion)
  154. Latin America Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Billion)
  155. Latin America Breast Market, By Region, From 2021 to 2026 (USD Billion)
  156. Latin America Lung Market, By Region, From 2021 to 2026 (USD Billion)
  157. Latin America Melanoma Market, By Region, From 2021 to 2026 (USD Billion)
  158. Latin America Colorectal Market, By Region, From 2021 to 2026 (USD Billion)
  159. Latin America Head & Neck Market, By Region, From 2021 to 2026 (USD Billion)
  160. Latin America Prostate Market, By Region, From 2021 to 2026 (USD Billion)
  161. Latin America Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Billion)
  162. Latin America Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Billion)
  163. Latin America Checkpoint inhibitors/immune modulators Market, By Region, From 2021 to 2026 (USD Billion)
  164. Latin America Therapeutic cancer vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  165. Latin America Oncolytic virus immunotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  166. Latin America Cytokines Market, By Region, From 2021 to 2026 (USD Billion)
  167. Latin America Adoptive T cell Transfer Market, By Region, From 2021 to 2026 (USD Billion)
  168. Latin America Adjuvant immunotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  169. Latin America Interferons Market, By Region, From 2021 to 2026 (USD Billion)
  170. Latin America Interleukins Market, By Region, From 2021 to 2026 (USD Billion)
  171. Latin America BCG Market, By Region, From 2021 to 2026 (USD Billion)
  172. Latin America Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Billion)
  173. Latin America Intravenous Market, By Region, From 2021 to 2026 (USD Billion)
  174. Latin America Oral Market, By Region, From 2021 to 2026 (USD Billion)
  175. Latin America Topical Market, By Region, From 2021 to 2026 (USD Billion)
  176. Latin America Intravesical Market, By Region, From 2021 to 2026 (USD Billion)
  177. Latin America Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Billion)
  178. Latin America hospitals Market, By Region, From 2021 to 2026 (USD Billion)
  179. Latin America Clinics Market, By Region, From 2021 to 2026 (USD Billion)
  180. Brazil Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Billion)
  181. Brazil Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Billion)
  182. Brazil Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Billion)
  183. Brazil Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Billion)
  184. Argentina Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Billion)
  185. Argentina Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Billion)
  186. Argentina Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Billion)
  187. Argentina Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Billion)
  188. Mexico Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Billion)
  189. Mexico Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Billion)
  190. Mexico Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Billion)
  191. Mexico Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Billion)
  192. Rest of Latin America Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Billion)
  193. Rest of Latin America Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Billion)
  194. Rest of Latin America Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Billion)
  195. Rest of Latin America Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Billion)
  196. Middle East & Africa Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Billion)
  197. Middle East & Africa Breast Market, By Region, From 2021 to 2026 (USD Billion)
  198. Middle East & Africa Lung Market, By Region, From 2021 to 2026 (USD Billion)
  199. Middle East & Africa Melanoma Market, By Region, From 2021 to 2026 (USD Billion)
  200. Middle East & Africa Colorectal Market, By Region, From 2021 to 2026 (USD Billion)
  201. Middle East & Africa Head & Neck Market, By Region, From 2021 to 2026 (USD Billion)
  202. Middle East & Africa Prostate Market, By Region, From 2021 to 2026 (USD Billion)
  203. Middle East & Africa Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Billion)
  204. Middle East & Africa Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Billion)
  205. Middle East & Africa Checkpoint inhibitors/immune modulators Market, By Region, From 2021 to 2026 (USD Billion)
  206. Middle East & Africa Therapeutic cancer vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  207. Middle East & Africa Oncolytic virus immunotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  208. Middle East & Africa Cytokines Market, By Region, From 2021 to 2026 (USD Billion)
  209. Middle East & Africa Adoptive T cell Transfer Market, By Region, From 2021 to 2026 (USD Billion)
  210. Middle East & Africa Adjuvant immunotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  211. Middle East & Africa Interferons Market, By Region, From 2021 to 2026 (USD Billion)
  212. Middle East & Africa Interleukins Market, By Region, From 2021 to 2026 (USD Billion)
  213. Middle East & Africa BCG Market, By Region, From 2021 to 2026 (USD Billion)
  214. Middle East & Africa Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Billion)
  215. Middle East & Africa Intravenous Market, By Region, From 2021 to 2026 (USD Billion)
  216. Middle East & Africa Oral Market, By Region, From 2021 to 2026 (USD Billion)
  217. Middle East & Africa Topical Market, By Region, From 2021 to 2026 (USD Billion)
  218. Middle East & Africa Intravesical Market, By Region, From 2021 to 2026 (USD Billion)
  219. Middle East & Africa Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Billion)
  220. Middle East & Africa hospitals Market, By Region, From 2021 to 2026 (USD Billion)
  221. Middle East & Africa Clinics Market, By Region, From 2021 to 2026 (USD Billion)
  222. Middle East Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Billion)
  223. Middle East Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Billion)
  224. Middle East Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Billion)
  225. Middle East Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Billion)
  226. Africa Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Billion)
  227. Africa Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Billion)
  228. Africa Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Billion)
  229. Africa Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample